TOKYO, Nov 10 (Reuters) - Astellas Pharma <4503.T>, Japan's No.2 drugmaker, said on Tuesday it will buy the rights to develop and sell U.S. firm Ironwood Pharmaceuticals' drug for irritable bowel syndrome in Japan and other parts of Asia.View the full article